查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1989977

腦腎上腺腦白質營養不良症市場：依治療方法、通路、最終用戶和患者年齡層分類－2026年至2032年全球市場預測

Cerebral Adrenoleukodystrophy Market by Treatment Type, Distribution Channel, End User, Patient Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，腎上腺腦白質營養不良症市值將達到 5.4723 億美元，到 2026 年將成長至 6.2224 億美元，到 2032 年將達到 14.3746 億美元，年複合成長率為 14.79%。

主要市場統計數據
基準年 2025 5.4723億美元
預計年份：2026年 6.2224億美元
預測年份 2032 14.3746億美元
複合年成長率 (%) 14.79%

對腦腎上腺腦白質營養不良的臨床複雜性、診斷緊迫性、治療需求及其對醫療保健政策制定者的影響進行關鍵性回顧。

腎上腺腦白質營養不良症 (CALD) 是兒童和成人神經病學領域最緊迫的神經遺傳學挑戰之一，其特徵是進行性去髓鞘化、發炎級聯反應以及患者臨床症狀迅速惡化。該疾病處於罕見疾病科學、先進生物製藥研發和複雜臨床管理路徑的交匯點，所有這些因素共同構成了一個對臨床醫生、患者家屬和行業相關人員至關重要的環境。鑑於症狀的多樣性和有效干預時機的有限性，相關人員需要將快速診斷與不斷發展的治療方法相結合，以改善治療效果。

不斷發展的基因改造策略、複雜的移植通訊協定和綜合護理模式如何重塑腦腎上腺腦白質營養不良的臨床路徑和相關人員的獎勵。

腦腎上腺腦白質營養不良的治療和護理格局正在經歷一場變革性的轉變，這主要得益於基因治療的創新、移植通訊協定的改進以及多學科診療模式的日趨成熟。基因修飾策略正從理論概念走向臨床應用，改變了臨床醫生評估患者合格、監測療效以及進行長期後續觀察的方式。同時，造血幹細胞移植的方法也在不斷發展，供體選擇演算法、預處理方案和支持性護理路徑的改進降低了早期併發症的發生率，並擴大了合格範圍。

制定營運和籌資策略，以減輕近期美國關稅調整對生物製藥生產、供應連續性和罕見疾病患者治療的連鎖反應。

美國近期政策的轉變和關稅調整，為從事先進生技藥品和孤兒藥治療領域的企業營運決策帶來了新的變數。影響進口原料、病毒載體、特殊試劑和精密儀器的關稅可能會增加投入成本，並使基因治療和生物製藥中間體生產企業的供應計劃更加複雜。這些變化會對契約製造協議、採購週期和庫存策略產生連鎖反應，因此需要建立更具韌性的供應商網路和緊急時應對計畫。

從細分的觀點治療方法、通路、最終用戶環境和每個年齡層的臨床需求聯繫起來，從而有助於制定策略和設計護理方案。

對治療方案和護理管道的細分理解有助於明確整個治療路徑中的臨床決策和商業性定位。分析治療類型後發現，基因治療和造血幹細胞移植是需要高度專業化的交付基礎設施和長期追蹤的治癒性治療選擇。在基因治療中，腺結合病毒載體和慢病毒載體方法的差異會影響載體的選擇、生產複雜性和調節終點。另一方面，造血幹細胞移植又分為異基因移植和自體移植，每種移植方式在捐贈者獲取、免疫風險和預處理方面都有不同的考量。包括抗發炎藥物和輔助性治療（例如「洛倫佐油」）在內的輔助藥物治療繼續用於控制症狀，並可能擴大根治性干預的治療機會。支持性護理，包括營養支持、物理治療和症狀治療，是功能性預後的基礎，需要多學科協作規劃以維持患者的生活品質。

區域基礎設施、監管要求和醫療保健服務模式如何影響美洲、歐洲、中東、非洲和亞太地區的醫療服務取得途徑和戰略重點？

區域趨勢對臨床實踐模式、監管參與以及先進治療方法的物流可行性有顯著影響。在美洲，健全的臨床試驗體系和不斷擴展的新生兒篩檢計畫正在改善早期診斷，而集中化的生物製造能力和支付方參與模式則正在影響商業性進入途徑。這些因素共同決定了醫療服務提供者和製造商在該地區如何優先考慮其臨床開發和打入市場策略。

在治療方法研發、專業製造、臨床中心和服務供應商方面的策略性定位決定了誰能夠為複雜的罕見疾病治療方法提供可靠且擴充性的解決方案。

目前，腦腎上腺腦白質營養不良相關解決方案的競爭格局呈現出領先治療方法開發商、專業契約製造製造商、卓越臨床中心和患者管理服務供應商能力融合的趨勢。領先的治療方法開發人員正致力於最佳化載體平台、耐久性測試和安全性監測，以建構差異化的臨床特性。同時，生產合作夥伴正在擴大產能、實施封閉式生產系統、降低批間差異並驗證檢驗，以支持監管申報。臨床中心正匯集各方專長，提供複雜的干涉療法、管理移植通訊協定並運作產生真實世界數據的縱向註冊登記系統。

為確保供應連續性、加快部署並展現永續的臨床價值，領導者需要立即實施以營運、證據產生和以患者為中心的措施。

業界領導者應優先考慮一系列切實可行的舉措，以提升患者就醫便利性、降低營運風險並加速實證醫學證據的產生。首先，應投資增強一體化供應鏈的韌性，具體措施包括：關鍵原料的認證供應商多元化；盡可能加快本地供應商的認證進程；以及建立能夠抵禦原料價格波動的合約框架。這些措施將降低生產中斷的風險，並確保治療交付時間的可預測性。其次，應建立協作式實證醫學聯盟，連接臨床中心、註冊機構和保險公司，以產生關於長期療效、安全性和成本效益的真實世界數據，從而為報銷談判和應用決策提供支援。

為了產生對策略規劃的實用見解，我們採用了多方面的調查方法，該方法結合了臨床證據的整合、與相關人員的對話、監管趨勢的監測和營運分析。

本分析的研究途徑整合了臨床文獻回顧、相關人員訪談、政策和監管監測以及營運評估，旨在建構疾病、治療方法和市場動態的全面觀點。臨床數據與已發表的試驗通訊協定、同行評審研究和共識指南進行交叉比對，以確保治療路徑和臨床決策點反映當前的臨床實踐。透過對臨床醫生、生產專家、保險公司和服務供應商的定向訪談，收集了相關人員的觀點，揭示了營運限制、推廣應用的促進因素以及保險公司的期望。

整合臨床機會、營運挑戰和協作重點，以確定治療進展是否能為腦腎上腺腦白質營養不良患者帶來持續改善。

腎上腺腦白質營養不良症的治療面臨著許多複雜挑戰，包括迫切的臨床需求、快速的治療方法創新以及確保安全用藥的嚴格操作要求。儘管基因修飾療法和先進的移植策略為改變疾病進程提供了切實可行的前景，但要實現持續療效，需要協調臨床時機、生產能力和支付方支持的准入模式。監管政策、本地基礎設施和供應鏈動態之間的相互作用將繼續決定哪些干預措施能為患者帶來持久的益處。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：腎上腺腦白質營養不良症市場（依治療方法）

  • 基因治療
    • 腺結合病毒載體
    • 慢病毒載體
  • 造血幹細胞移植
    • 同種異體移植
    • 自體移植
  • 藥物治療
    • 抗發炎藥
    • 洛倫佐石油
  • 支持性護理
    • 營養支持
    • 物理治療
    • 症狀治療

第9章：腎上腺腦白質營養不良症市場：依通路分類

  • 家庭醫療保健服務
  • 醫院藥房
  • 專科藥房

第10章：腎上腺腦白質營養不良症市場：依最終用戶分類

  • 居家照護提供者
  • 醫院
  • 專科診所

第11章：依患者年齡層分類的腎上腺腦白質營養不良症市場

  • 成年患者
  • 兒童患者

第12章：腦腎上腺腦白質營養不良症市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：腦腎上腺腦白質營養不良症市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：腎上腺腦白質營養不良症市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國腎上腺腦白質營養不良症市場

第16章：中國腎上腺腦白質營養不良症市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abeona Therapeutics Inc.
  • Apollo Therapeutics
  • BioMarin Pharmaceutical Inc.
  • bluebird bio, Inc.
  • BridgeBio Pharma
  • Eunice Kennedy Shriver National Institute
  • Homology Medicines
  • MedDay Pharmaceuticals
  • Minoryx Therapeutics
  • Novartis AG
  • Orchard Therapeutics
  • Passage Bio
  • Pfizer Inc.
  • Polaryx Therapeutics
  • PTC Therapeutics
  • Regenxbio Inc.
  • Sage Therapeutics
  • Sanofi SA
  • SOM Biotech
  • Takeda Pharmaceutical Company Ltd.
Product Code: MRR-CD5A9334D6B7

The Cerebral Adrenoleukodystrophy Market was valued at USD 547.23 million in 2025 and is projected to grow to USD 622.24 million in 2026, with a CAGR of 14.79%, reaching USD 1,437.46 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 547.23 million
Estimated Year [2026] USD 622.24 million
Forecast Year [2032] USD 1,437.46 million
CAGR (%) 14.79%

A focused synthesis of the clinical complexity, diagnostic urgency, and therapeutic imperatives that define cerebral adrenoleukodystrophy and its implications for healthcare decision-makers

Cerebral adrenoleukodystrophy (CALD) represents one of the most urgent neurogenetic challenges in pediatric and adult neurology, characterized by progressive demyelination, inflammatory cascades, and rapid clinical decline in affected individuals. The condition sits at the confluence of rare disease science, advanced biologics development, and complex clinical management pathways, which together create a high-stakes environment for clinicians, families, and industry stakeholders. Given the heterogeneity of presentation and the narrow therapeutic windows for effective intervention, stakeholders must align diagnostic agility with evolving therapeutic modalities to improve outcomes.

Over recent years, advances in molecular diagnostics, newborn screening expansion, and heightened awareness among specialist centers have sharpened the clinical pathway for identification and early referral. Consequently, this landscape places new pressures on supply chains, reimbursement strategies, and care coordination infrastructures. Translational research continues to interrogate pathophysiologic mechanisms while clinical programs work to optimize timing of intervention. In this context, decision-makers must synthesize clinical evidence, regulatory developments, and operational realities to design programs that are both patient-centric and commercially viable.

How evolving gene-modifying strategies, refined transplantation protocols, and integrated care models are reshaping clinical pathways and stakeholder incentives in cerebral adrenoleukodystrophy

The therapeutic and care landscape for cerebral adrenoleukodystrophy is undergoing transformative shifts driven by innovations in gene therapy, refinements in transplantation protocols, and the maturation of multidisciplinary care models. Gene-modifying strategies have moved from theoretical constructs to clinical-stage interventions, prompting changes in how clinicians evaluate candidacy, monitor efficacy, and manage long-term surveillance. Concurrently, hematopoietic stem cell transplantation approaches have evolved with better donor selection algorithms, conditioning regimens, and supportive care pathways that reduce early morbidity and broaden eligibility criteria.

Pharmacologic approaches continue to play a complementary role, particularly in symptom control and inflammation management, while supportive care modalities increasingly focus on quality-of-life optimization across the disease trajectory. Additionally, shifts in payer expectations and regulatory frameworks are accelerating adoption pathways for high-cost, high-complexity therapies, which in turn incentivizes providers and manufacturers to build robust evidence generation plans. As a result, the ecosystem is transitioning from episodic reactive care toward integrated, longitudinal models that prioritize early detection and durable clinical benefit. These changes necessitate strategic alignment among clinical, manufacturing, and commercial functions to capture value and improve patient outcomes.

Operational and procurement strategies to mitigate the cascading effects of recent United States tariff adjustments on biologics manufacturing, supply continuity, and patient access for rare disease therapies

Recent policy shifts and tariff realignments in the United States have introduced new variables to the operational calculus for organizations active in advanced biologics and rare disease therapeutics. Tariffs that affect imported raw materials, viral vectors, specialized reagents, and precision instrumentation can raise input costs and complicate supply planning for manufacturing suites that produce gene therapies and biologic intermediates. These changes ripple through contract manufacturing arrangements, procurement cycles, and inventory strategies, creating a need for more resilient supplier networks and contingency plans.

In response, industry actors have adjusted sourcing strategies by diversifying supplier footprints, accelerating local qualification of critical inputs, and negotiating longer-term agreements to stabilize pricing and delivery. Regulatory bodies and industry consortia have also engaged in dialogue to clarify harmonized customs classifications for biologic inputs and to seek exemptions or mitigations where tariffs would meaningfully impede access to lifesaving therapies. For clinicians and care networks, the most tangible effects manifest as potential shifts in lead times for therapeutic products and increased emphasis on early enrollment in clinical programs to buffer against distribution delays. Looking forward, organizations that proactively adapt procurement, manufacturing, and contractual frameworks will better navigate the operational consequences and maintain continuity of patient access.

Detailed segmentation-driven perspectives that connect therapeutic modalities, distribution pathways, end-user environments, and age-specific clinical imperatives to inform strategy and care design

Segment-level understanding of therapeutic options and care channels clarifies clinical decision-making and commercial positioning across treatment pathways. When analyzing treatment type, gene therapy and hematopoietic stem cell transplantation emerge as curative-intent options that require highly specialized delivery infrastructures and long-term follow-up; within gene therapy, distinction between adeno associated viral vector and lentiviral vector approaches influences vector selection, manufacturing complexity, and regulatory endpoints, while hematopoietic stem cell transplantation subdivides into allogeneic and autologous pathways that carry differing donor sourcing, immunologic risk, and conditioning considerations. Complementary pharmacotherapy-comprising anti-inflammatory agents and adjuvant strategies such as Lorenzo's Oil-continues to provide symptomatic control and may extend therapeutic windows for definitive interventions. Supportive care components including nutritional support, physical therapy, and symptomatic treatment underpin functional outcomes and require coordinated multidisciplinary plans to sustain quality of life.

Distribution channels and end-user environments further shape patient journeys and access models. Home healthcare services, hospital pharmacies, and specialty pharmacies each play distinct roles in enabling continuity of care, with home-based programs facilitating outpatient management and hospital-centered services supporting acute and procedural interventions. End users such as home care providers, hospitals, and specialty clinics must therefore align protocols and training to ensure safe administration, monitoring, and escalation pathways. Finally, patient age grouping into adult and pediatric cohorts introduces divergent clinical priorities: pediatric populations demand early detection and time-sensitive therapeutic interventions, whereas adult cohorts frequently require tailored supportive care strategies and longitudinal neurocognitive monitoring. Integrating these segmentation lenses enables stakeholders to design targeted pathways that are clinically appropriate and operationally feasible.

How distinct regional infrastructures, regulatory expectations, and care delivery models shape access pathways and strategic priorities across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics exert a pronounced influence on clinical practice patterns, regulatory engagement, and the logistical feasibility of delivering advanced therapies. In the Americas, robust clinical trial ecosystems and expanding newborn screening programs have improved early diagnosis, while concentrated biomanufacturing capabilities and payer engagement models influence commercial access pathways. These elements together shape how providers and manufacturers prioritize clinical development and market entry strategies in this geography.

In the Europe, Middle East & Africa region, heterogeneous regulatory frameworks and diverse reimbursement landscapes require more nuanced market access strategies that account for country-level policy, center-of-excellence distribution models, and cross-border referral patterns. Stakeholders often need to establish local partnerships and evidence generation plans attuned to regional HTA expectations. The Asia-Pacific region demonstrates rapidly growing clinical research activity, increasing investment in local manufacturing, and varied adoption timelines across national health systems; here, stakeholders must navigate differences in diagnostic infrastructure and adapt to regional supply chain dynamics. Across all regions, coordinated stakeholder engagement, investment in local capacity building, and adaptable distribution strategies remain essential to expanding access while maintaining clinical quality.

Strategic positioning across therapy development, specialized manufacturing, clinical centers, and service providers that determines who can deliver reliable, scalable solutions for complex rare disease therapies

The contemporary competitive landscape for cerebral adrenoleukodystrophy-related solutions is characterized by a convergence of capabilities across developers of advanced therapies, specialized contract manufacturers, clinical centers of excellence, and service providers that support patient management. Leading therapy developers are investing in vector platform optimization, durability studies, and safety monitoring to build differentiated clinical profiles, while manufacturing partners scale capacity, implement closed-system processing, and validate assays that reduce batch variability and support regulatory submissions. Clinical centers are concentrating expertise to deliver complex interventions, manage transplant protocols, and run longitudinal registries that generate real-world evidence.

At the same time, commercial and operational service providers-ranging from specialty pharmacists to logistics firms experienced in cold-chain biologics-are evolving their service offerings to meet the unique requirements of gene-modifying products and cellular therapies. Strategic partnerships that integrate clinical trial networks with manufacturing and distribution capabilities increasingly determine who can deliver therapies reliably at scale. Companies that align R&D priorities with demonstrable operational resilience, transparent safety surveillance, and proactive payer engagement will likely maintain stronger positioning as the field moves from early-stage innovation toward broader clinical adoption.

Operational, evidence-generation, and patient-centric initiatives that leaders can implement immediately to secure supply continuity, accelerate adoption, and demonstrate durable clinical value

Industry leaders should prioritize a set of actionable initiatives that strengthen patient access, reduce operational risk, and accelerate evidence generation. First, invest in integrated supply-chain resilience by diversifying qualified suppliers for critical inputs, accelerating local supplier qualification where feasible, and establishing contractual frameworks that protect against input volatility. These measures will reduce the risk of production interruptions and support predictable treatment delivery timing. Second, develop collaborative evidence-generation consortia that link clinical centers, registries, and payers to produce real-world data on longitudinal outcomes, safety, and cost-effectiveness that support reimbursement negotiations and adoption decisions.

Third, create patient-centered delivery models that expand safe home-based care where clinically appropriate while ensuring robust training and escalation protocols for community providers. Fourth, adopt modular manufacturing and platform technologies that reduce per-batch variability and shorten time-to-release, thereby improving responsiveness to clinical demand. Finally, engage proactively with regulatory and payer stakeholders to clarify value frameworks, seek accelerated pathways when justified by clinical benefit, and co-design outcome-based contracting that aligns payment with sustained patient outcomes. By implementing these interconnected steps, leaders can balance near-term operational needs with the long-term objective of durable patient benefit.

A multi-source methodology that combines clinical evidence synthesis, stakeholder engagement, regulatory monitoring, and operational analysis to produce actionable insights for strategic planning

The research approach underpinning this analysis integrates clinical literature review, stakeholder interviews, policy and regulatory monitoring, and operational assessment to build a holistic perspective on disease, therapy, and market dynamics. Clinical inputs were triangulated with published trial protocols, peer-reviewed studies, and consensus guidance to ensure that therapeutic pathways and clinical decision points reflect current practice. Stakeholder perspectives were captured through targeted interviews with clinicians, manufacturing specialists, payers, and service providers to surface operational constraints, adoption drivers, and payer expectations.

Operational and policy analyses drew on customs and trade policy documents, supply chain assessments, and manufacturing capability studies to evaluate how tariffs, procurement practices, and logistics influence access and cost structures. Throughout, the methodology emphasized cross-validation among multiple data streams to reduce bias and to highlight areas where evidence gaps warrant future research. The result is a pragmatic synthesis that balances clinical nuance with operational realism, offering stakeholders both the context and the operational insights necessary to inform strategic planning.

Synthesis of clinical opportunity, operational imperatives, and collaborative priorities that will determine whether therapeutic advances translate into durable improvement for patients with cerebral adrenoleukodystrophy

Cerebral adrenoleukodystrophy occupies a complex intersection of urgent clinical need, rapid therapeutic innovation, and demanding operational requirements for safe delivery. Advances in gene-modifying therapies and refined transplantation strategies provide realistic prospects for altering disease trajectory, but achieving durable impact depends on aligning clinical timing, manufacturing resilience, and payer-supported access models. The interplay between regulatory policy, regional infrastructure, and supply-chain dynamics will continue to shape which interventions translate into sustained patient benefit.

Going forward, successful programs will integrate early detection initiatives, robust real-world evidence generation, and flexible operations that anticipate policy-induced supply disruptions. Cross-sector collaboration among developers, clinical centers, and service providers will remain essential to scale complex interventions while safeguarding quality and affordability. By focusing on these interconnected priorities, stakeholders can meaningfully improve outcomes for affected patients and their families while building sustainable pathways for advanced therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cerebral Adrenoleukodystrophy Market, by Treatment Type

  • 8.1. Gene Therapy
    • 8.1.1. Adeno Associated Viral Vector
    • 8.1.2. Lentiviral Vector
  • 8.2. Hematopoietic Stem Cell Transplantation
    • 8.2.1. Allogeneic Transplantation
    • 8.2.2. Autologous Transplantation
  • 8.3. Pharmacotherapy
    • 8.3.1. Anti-Inflammatories
    • 8.3.2. Lorenzo's Oil
  • 8.4. Supportive Care
    • 8.4.1. Nutritional Support
    • 8.4.2. Physical Therapy
    • 8.4.3. Symptomatic Treatment

9. Cerebral Adrenoleukodystrophy Market, by Distribution Channel

  • 9.1. Home Healthcare Services
  • 9.2. Hospital Pharmacies
  • 9.3. Specialty Pharmacies

10. Cerebral Adrenoleukodystrophy Market, by End User

  • 10.1. Home Care Providers
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Cerebral Adrenoleukodystrophy Market, by Patient Age Group

  • 11.1. Adult Patients
  • 11.2. Pediatric Patients

12. Cerebral Adrenoleukodystrophy Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cerebral Adrenoleukodystrophy Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cerebral Adrenoleukodystrophy Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Cerebral Adrenoleukodystrophy Market

16. China Cerebral Adrenoleukodystrophy Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abeona Therapeutics Inc.
  • 17.6. Apollo Therapeutics
  • 17.7. BioMarin Pharmaceutical Inc.
  • 17.8. bluebird bio, Inc.
  • 17.9. BridgeBio Pharma
  • 17.10. Eunice Kennedy Shriver National Institute
  • 17.11. Homology Medicines
  • 17.12. MedDay Pharmaceuticals
  • 17.13. Minoryx Therapeutics
  • 17.14. Novartis AG
  • 17.15. Orchard Therapeutics
  • 17.16. Passage Bio
  • 17.17. Pfizer Inc.
  • 17.18. Polaryx Therapeutics
  • 17.19. PTC Therapeutics
  • 17.20. Regenxbio Inc.
  • 17.21. Sage Therapeutics
  • 17.22. Sanofi S.A.
  • 17.23. SOM Biotech
  • 17.24. Takeda Pharmaceutical Company Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY ADENO ASSOCIATED VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY ADENO ASSOCIATED VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY ADENO ASSOCIATED VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY LENTIVIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY LENTIVIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY LENTIVIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY ALLOGENEIC TRANSPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY ALLOGENEIC TRANSPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY ALLOGENEIC TRANSPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY AUTOLOGOUS TRANSPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY AUTOLOGOUS TRANSPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY AUTOLOGOUS TRANSPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY LORENZO'S OIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY LORENZO'S OIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY LORENZO'S OIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY NUTRITIONAL SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY NUTRITIONAL SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY NUTRITIONAL SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PHYSICAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PHYSICAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SYMPTOMATIC TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SYMPTOMATIC TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SYMPTOMATIC TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HOME HEALTHCARE SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HOME HEALTHCARE SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HOME HEALTHCARE SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HOME CARE PROVIDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HOME CARE PROVIDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HOME CARE PROVIDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GCC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. GCC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2032 (USD MILLION)
  • TABLE 160. GCC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. GCC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 162. GCC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. GCC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. GCC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. G7 CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. G7 CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2032 (USD MILLION)
  • TABLE 187. G7 CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. G7 CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 189. G7 CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. G7 CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. G7 CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. NATO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. NATO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2032 (USD MILLION)
  • TABLE 196. NATO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 197. NATO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 198. NATO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. NATO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. NATO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)